Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

By D. Kendall, M. Riddle, J. Rosenstock, Dongliang Zhuang, Dennis D. Kim, M. Fineman, A. Baron. Diabetes Care, 2005

1,265 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2012, background): “two-drug combination that is not yet or no longer achieving the glycaemic target [83–86].”
Gut hormones and the regulation of energy homeostasis (2006, background): “Interestingly, in phase III 30-week clinical trials, exenatide significantly reduced body weight in treated diabetic”
Update on the treatment of type 2 diabetes mellitus. (2016, background): “Moreover, mean change in body weight from baseline was greater in the exenatide group (-1.6 to -2.8 kg) than in the placebo group (-0.3 to -0.9 kg) [180-182] .”
Incretin-based therapies for type 2 diabetes mellitus (2009, background): “Three pivotal, phase III clinical trials, each of 30 weeks duration, examined the efficacy of twice-daily injections of 5 µg or 10 µg exenatide in individuals who had T2DM that was inadequately controlled with a sulfonylurea and/or metformin”
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, background): “…presence did not seem to impact the degree of glycemic control, and 2), increasing titer of antibody also did not seem to be reflected in worsening blood glucose control (Buse et al., 2004; DeFronzo et al., 2005; Heine et al., 2005; Kendall et al., 2005; Nauck et al., 2007a; Zinman et al., 2007).”